Composition of dialysis liquid comprising crystallisation inhibitor substances

Abstract

This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.

1 . Composition that comprises crystallisation inhibitory substances selected from the list that comprises inositol phosphate, bisphosphonate, the pharmaceutically acceptable salts or any of the combinations thereof, to be used in the preparation of a dialysis liquid. 
     
     
         2 . Composition as claimed in  claim 1 , where the crystallisation inhibitory substance is the inositol phosphate that contains between 1 and 6 phosphate groups. 
     
     
         3 . Composition as claimed in  claim 2 , where the inositol phosphate is inositol hexaphosphate. 
     
     
         4 . Composition as claimed in  claim 3 , where the inositol phosphate is myo-inositol hexaphosphate. 
     
     
         5 . Composition as claimed in  claim 1 , where the bisphosphonate is selected from the list that comprises etidronic acid, alendronic acid, risedronic acid, zoledronic acid, tiludronic acid, pamidronic acid, clodronic acid, ibandronic acid, the salts or any of the combinations thereof. 
     
     
         6 . Composition as claimed in any of  claims 1  to  5 , which additionally comprises pyrophosphate. 
     
     
         7 . Composition as claimed in any of  claims 1  to  6 , where the crystallisation inhibitory substances are in a concentration of between 0.01 μM and 0.1 M. 
     
     
         8 . Composition as claimed in  claim 7 , where the crystallisation inhibitory substances are in a concentration of between 0.1 μM and 10 mM. 
     
     
         9 . Composition as claimed in  claim 8 , where the crystallisation inhibitory substances are in a concentration of between 0.1 μM and 5 mM. 
     
     
         10 . Dialysis liquid that comprises crystallisation inhibitory substances selected from the list that comprises inositol phosphate, bisphosphonate, the pharmaceutically acceptable salts or any of the combinations thereof. 
     
     
         11 . Use of the dialysis liquid as claimed in  claim 10 , for haemodialysis or peritoneal dialysis. 
     
     
         12 . Composition that comprises inositol phosphate and/or any of the salts thereof in a form adapted for intravenous administration, to be used in the treatment or prevention of pathological processes associated with the de-regularisation of the physiologically adequate levels of said substances in the blood plasma. 
     
     
         13 . Composition as claimed in  claim 12 , where the inositol phosphate contains between 1 and 6 phosphate groups. 
     
     
         14 . Composition as claimed in  claim 13 , where the inositol phosphate is inositol hexaphosphate. 
     
     
         15 . Composition as claimed in  claim 14 , where the inositol phosphate is myo-inositol hexaphosphate. 
     
     
         16 . Composition as claimed in any of  claims 12  to  15 , where the dose of inositol phosphate and/or any of the pharmaceutically acceptable salts thereof is between 1 nmol/kg and 0.1 mol/kg. 
     
     
         17 . Composition as claimed in any of  claims 12  to  16 , which additionally comprises pyrophosphate. 
     
     
         18 . Composition as claimed in any of  claims 12  to  17 , where the treatment or prevention of de-regularisation is performed by maintaining of increasing the levels of said substances in the plasma of a person subjected to dialysis. 
     
     
         19 . Combined preparation that comprises, at least, a composition that comprises crystallisation inhibitory substances selected from the list that comprises inositol phosphate, bisphosphonate, the pharmaceutically acceptable salts or any of the combinations thereof, and a dialysis liquid to be used separately, simultaneously or sequentially in the treatment or prevention of pathological processes associated with the de-regularisation of the physiologically adequate levels of said substances in the plasma of patients subjected to dialysis. 
     
     
         20 . Combined preparation as claimed in  claim 19 , where the composition is in a form adapted for intravenous administration.